Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

526
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
526
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

252
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
252
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

370
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
370
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

193
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
193
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

36
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
36
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

34
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methylation plus alpha-fetoprotein blood test for early detection of HCC in at-risk populations.

Hepatology communications·2026
Same author

A Major Step toward a Cure for Hepatitis B Infection.

The New England journal of medicine·2026
Same author

Hepatitis B: A Review.

JAMA·2026
Same author

Validation of longitudinal biomarker screening algorithms for HCC detection in patients with cirrhosis.

Hepatology communications·2026
Same author

A Self-Reported Electronic Body Map Identifies Distinct Clinical Pain Phenotypes in Chronic Pancreatitis.

Clinical and translational gastroenterology·2026
Same author

Animal Naming Test Predicts Future Overt Hepatic Encephalopathy.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Related Experiment Video

Updated: Oct 22, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.1K

Microbiome therapeutics for hepatic encephalopathy.

Patricia P Bloom1, Elliot B Tapper1, Vincent B Young2

  • 1Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, USA.

Journal of Hepatology
|August 28, 2021
PubMed
Summary

Microbiome-targeted therapies show promise for hepatic encephalopathy (HE), a cirrhosis complication. Challenges remain in achieving sustainable changes and predictable outcomes for HE patients.

Keywords:
ammoniacirrhosisfecal transplantlactuloseprobioticrifaximin

More Related Videos

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice
07:49

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Published on: June 2, 2022

3.4K
A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model
08:14

A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model

Published on: February 28, 2018

9.0K

Related Experiment Videos

Last Updated: Oct 22, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.1K
Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice
07:49

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Published on: June 2, 2022

3.4K
A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model
08:14

A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model

Published on: February 28, 2018

9.0K

Area of Science:

  • Gastroenterology and Hepatology
  • Microbiome Research
  • Neuroscience

Background:

  • Hepatic encephalopathy (HE) is a neuropsychiatric complication of cirrhosis.
  • Microbiota-host interactions are crucial in HE pathogenesis.
  • Current treatments aim to modulate the gut microbiome.

Purpose of the Study:

  • To review microbiome-targeted therapies for hepatic encephalopathy.
  • To assess the efficacy and challenges of these therapies.
  • To propose future directions for microbiome therapeutics in HE.

Main Methods:

  • Review of existing literature on microbiome-targeted therapies for HE.
  • Analysis of different therapeutic approaches including prebiotics, probiotics, FMT, antibiotics, postbiotics, and absorbents.
  • Evaluation of clinical outcomes and challenges associated with these interventions.

Main Results:

  • Lactulose and rifaximin have shown success in managing HE.
  • Probiotics and fecal microbiota transplant (FMT) demonstrate potential therapeutic benefits.
  • Microbiome therapies face challenges like microbial resilience and unpredictable outcomes.

Conclusions:

  • Microbiome-targeted therapies offer a promising avenue for HE treatment.
  • Further research is needed to overcome challenges in microbiome modulation.
  • Personalized approaches and rigorous trial design are essential for future HE microbiome therapeutics.